Represents Grant table in the DB

GET /v1/grants?page%5Bnumber%5D=1392&sort=funder
HTTP 200 OK
Allow: GET, POST, HEAD, OPTIONS
Content-Type: application/vnd.api+json
Vary: Accept

{
    "links": {
        "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder",
        "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1442&sort=funder",
        "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=funder",
        "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=funder"
    },
    "data": [
        {
            "type": "Grant",
            "id": "11600",
            "attributes": {
                "award_id": "5R21AI161061-02",
                "title": "Covalent inhibitors of host cell entry by SARS-CoV-2 for treatment of COVID-19",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 6115,
                        "first_name": "DIPANWITA",
                        "last_name": "Basu",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-20",
                "end_date": "2024-03-31",
                "award_amount": 236100,
                "principal_investigator": {
                    "id": 6116,
                    "first_name": "Matthew",
                    "last_name": "Bogyo",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 266,
                            "ror": "https://ror.org/00f54p054",
                            "name": "Stanford University",
                            "address": "",
                            "city": "",
                            "state": "CA",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 266,
                    "ror": "https://ror.org/00f54p054",
                    "name": "Stanford University",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Current strategies to overcome virus outbreaks are focused on development of effective vaccines as well as novel treatments that can either block infection or prevent mortality from the resulting disease. One of the strategies that has shown promise is the use of serum from patients who have recovered from infection. This strategy relies on the presence of high titers of neutralizing antibodies that bind to antigens on the virus and block uptake into host cells. For the SARS-CoV-2 virus this requires antibodies that bind to regions on the receptor binding domain (RBD) of the viral ‘spike’ (S) protein and block its interaction with the host receptor, angiotensin converting enzyme 2 (ACE2). Significant efforts over the past 15 years of studies on related coronaviruses has produced a detailed picture of the interactions between these two protein domains. These studies have facilitated strategies to select optimal neutralizing antibodies likely to have the greatest therapeutic value. While antibodies are effective biological therapies, they suffer from limitations that make their widespread use for a global pandemic limited. This includes the high cost of production, poor uptake by oral or localized administration and general incompatibility with long-term storage and stockpiling. Furthermore, interactions with the target viral proteins are reversible and can be rendered ineffective for antibody neutralization through single point mutations in virus variants. In this proposal, we outline plans to develop a phage display screening approach to identify synthetic cyclic peptides that carry a covalent ‘warhead’ to induce specific and permanent binding to the SARS-CoV-2 S protein at highly conserved and functionally important residues. This approach will lead to the identification of fully synthetic molecules that irreversibly block key interactions between the S protein RBD and the host cell receptor, ACE2. Such molecules will possess the selectivity of antibodies but can be synthesized and handled like small molecule drugs. Furthermore, their covalent binding mode will lead to prolonged therapeutic effects and reduced ability to induce resistance causing mutations in the S protein.",
                "keywords": [
                    "2019-nCoV",
                    "ACE2",
                    "Animal Model",
                    "Antibodies",
                    "Antigens",
                    "Azoles",
                    "Bacteriophages",
                    "Binding",
                    "Biological Assay",
                    "Biological Response Modifier Therapy",
                    "COVID-19",
                    "COVID-19 therapeutics",
                    "COVID-19 treatment",
                    "Cell model",
                    "Cells",
                    "Chemistry",
                    "China",
                    "Complex",
                    "Coronavirus",
                    "Cyclic Peptides",
                    "Development",
                    "Disease",
                    "Disease Outbreaks",
                    "Enzyme-Linked Immunosorbent Assay",
                    "Fluorides",
                    "Fluorine",
                    "Future",
                    "Goals",
                    "Health",
                    "Human",
                    "Infection",
                    "Knowledge",
                    "Libraries",
                    "Ligand Binding",
                    "Malignant Neoplasms",
                    "Mass Spectrum Analysis",
                    "Methods",
                    "Modification",
                    "Mutation",
                    "Oral",
                    "Patients",
                    "Peptide Hydrolases",
                    "Phage Display",
                    "Pharmaceutical Preparations",
                    "Point Mutation",
                    "Production",
                    "Proteins",
                    "Proteomics",
                    "Reaction",
                    "Receptor Cell",
                    "Resistance",
                    "Resolution",
                    "SARS-CoV-2 infection",
                    "SARS-CoV-2 spike protein",
                    "Serum",
                    "Site",
                    "Structure",
                    "Sulfur",
                    "Surface",
                    "Technology",
                    "Tertiary Protein Structure",
                    "Test Result",
                    "Testing",
                    "Therapeutic",
                    "Therapeutic Effect",
                    "Therapeutic Uses",
                    "Time",
                    "Tyrosine",
                    "Vaccines",
                    "Variant",
                    "Viral",
                    "Viral Proteins",
                    "Virus",
                    "Virus Diseases",
                    "cost",
                    "economic impact",
                    "high reward",
                    "high risk",
                    "in vivo",
                    "inhibitor",
                    "lead optimization",
                    "mortality",
                    "neutralizing antibody",
                    "novel",
                    "novel coronavirus",
                    "pandemic disease",
                    "pathogen",
                    "prevent",
                    "protein protein interaction",
                    "receptor",
                    "receptor binding",
                    "screening",
                    "small molecule",
                    "success",
                    "uptake",
                    "validation studies",
                    "viral outbreak"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11601",
            "attributes": {
                "award_id": "5R21AI161437-02",
                "title": "Profiling the immune response to convalescent plasma therapy during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 26918,
                        "first_name": "Michelle Marie",
                        "last_name": "Arnold",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-13",
                "end_date": "2024-03-31",
                "award_amount": 245625,
                "principal_investigator": {
                    "id": 6138,
                    "first_name": "Jay H.",
                    "last_name": "Bream",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 344,
                            "ror": "https://ror.org/00za53h95",
                            "name": "Johns Hopkins University",
                            "address": "",
                            "city": "",
                            "state": "MD",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 344,
                    "ror": "https://ror.org/00za53h95",
                    "name": "Johns Hopkins University",
                    "address": "",
                    "city": "",
                    "state": "MD",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The COVID-19 pandemic continues to grow at an exponential pace around the globe threatening health systems and the world economy. In the 9 months since the novel SARS-CoV-2 virus was identified as the cause of the life-threatening disease COVID-19, there have been over 20.6 million confirmed cases and over 750,000 deaths globally. With few options for treatment and no vaccine, the immediate outlook remains grim. Even in less severe cases, illness can be prolonged, recovery slow with long term consequences, such as immunity to re-infection and chronic complications remain largely unknown. Convalescent plasma from recovered individuals is being increasingly used as a stopgap treatment to mitigate disease morbidity and mortality and slow the spread of SARS-CoV-2 infection. Although COVID-19 convalescent plasma appears to be well-tolerated and there is general enthusiasm for the treatment, randomized clinical trials will be required to determine efficacy not to mention optimum delivery. Surprisingly, convalescent plasma therapy (CPT) has been used historically for the treatment and prevention of numerous infectious diseases, but the mechanisms of action are not fully understood. Likewise, the effects of CPT on the host immune response to the specific pathogen are not well defined. The primary goal of this application is to identify cellular and molecular immune signatures that predict COVID-19 outcomes and clinical response to therapy. We propose to leverage samples from ongoing convalescent plasma clinical trials at Johns Hopkins to link CPT-induced immune signatures with clinical outcomes. We will utilize a unique pipeline of advanced flow cytometry, single cell next generation sequencing and antibody profiling to provide a focused map charting the effects of CPT on SARS-CoV-2- specific T cells and antibody. We will determine the COVID-19 antibody profile and neutralization capacity in convalescent donors and define how CPT subsequently shapes the COVID-19 antibody profile at epitope resolution in recipients. These exploratory studies will provide a basis for identifying disease-associated immune signatures with prognostic and/or predictive value which is a critical step in identifying targets for intervention and correlates of protection.",
                "keywords": [
                    "2019-nCoV",
                    "Acute Disease",
                    "Acute Respiratory Distress Syndrome",
                    "Adrenal Cortex Hormones",
                    "Adult",
                    "Anti-Inflammatory Agents",
                    "Antibodies",
                    "Antibody Repertoire",
                    "Antibody Response",
                    "Antigen-Antibody Complex",
                    "Antiviral Agents",
                    "Automobile Driving",
                    "Biological Assay",
                    "Blood",
                    "COVID-19",
                    "COVID-19 pandemic",
                    "COVID-19 pathogenesis",
                    "COVID-19 patient",
                    "Cells",
                    "Cessation of life",
                    "Chronic",
                    "Clinical",
                    "Clinical Trials",
                    "Communicable Diseases",
                    "Data",
                    "Development",
                    "Dexamethasone",
                    "Diffuse",
                    "Disease",
                    "Disease Progression",
                    "Effectiveness",
                    "Epitopes",
                    "Flow Cytometry",
                    "Funding",
                    "Goals",
                    "Health system",
                    "Healthcare Systems",
                    "Hospitalization",
                    "Human",
                    "Immune",
                    "Immune Plasma",
                    "Immune response",
                    "Immunity",
                    "Immunoglobulin G",
                    "Immunoglobulins",
                    "Immunologics",
                    "Individual",
                    "Infection",
                    "Inflammatory Response",
                    "Integration Host Factors",
                    "Intervention",
                    "Life",
                    "Link",
                    "Maps",
                    "Measures",
                    "Mediating",
                    "Molecular",
                    "Monitor",
                    "Morbidity - disease rate",
                    "N-terminal",
                    "Newly Diagnosed",
                    "Nucleocapsid Proteins",
                    "Outcome",
                    "Pathology",
                    "Patients",
                    "Peripheral Blood Mononuclear Cell",
                    "Pharmaceutical Preparations",
                    "Plasma",
                    "Plasma Proteins",
                    "Predictive Value",
                    "Predisposition",
                    "Prevention",
                    "Preventive vaccine",
                    "Property",
                    "Proteins",
                    "Public Health",
                    "Randomized Controlled Clinical Trials",
                    "Recovery",
                    "Resolution",
                    "SARS-CoV-2 antibody",
                    "SARS-CoV-2 infection",
                    "Sampling",
                    "Serology test",
                    "Shapes",
                    "Standardization",
                    "Subgroup",
                    "Supportive care",
                    "System",
                    "T cell receptor repertoire sequencing",
                    "T cell response",
                    "T-Lymphocyte",
                    "Technology",
                    "Therapeutic",
                    "Therapeutic Effect",
                    "Time",
                    "Tissues",
                    "Vaccines",
                    "Virus",
                    "Work",
                    "adaptive immune response",
                    "adaptive immunity",
                    "airway inflammation",
                    "antigen-specific T cells",
                    "burden of illness",
                    "comparison control",
                    "convalescent plasma",
                    "cytokine",
                    "density",
                    "effective therapy",
                    "immune activation",
                    "improved",
                    "infectious disease treatment",
                    "insight",
                    "mortality",
                    "neutralizing antibody",
                    "new technology",
                    "next generation sequencing",
                    "novel",
                    "pathogen",
                    "predictive signature",
                    "prevent",
                    "prognostic value",
                    "randomized  clinical trials",
                    "remdesivir",
                    "response",
                    "severe COVID-19",
                    "single-cell RNA sequencing",
                    "therapy outcome",
                    "tool",
                    "treatment response",
                    "viral RNA"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11602",
            "attributes": {
                "award_id": "5R03CA270854-02",
                "title": "Targeting Lung Tissue Resident NK Cells with Inhaled IL-15 and TIGIT Blockade in Osteosarcoma",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Cancer Institute (NCI)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 21448,
                        "first_name": "CONNIE L",
                        "last_name": "Sommers",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-01",
                "end_date": "2024-03-31",
                "award_amount": 75733,
                "principal_investigator": {
                    "id": 27541,
                    "first_name": "Robert J.",
                    "last_name": "Canter",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": []
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 746,
                    "ror": "",
                    "name": "UNIVERSITY OF CALIFORNIA AT DAVIS",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Cytokine immunotherapies, such as IL-2 and more recently IL-15, have been used to stimulate endogenous cytotoxic natural killer (NK) and T cell responses against advanced cancers and to support adoptively transferred lymphokine-activated killer cells. While responses have been achieved in some patients, the use of IL-2 and IL- 15 has been hampered by modest benefits with the risk of severe systemic toxicity, particularly when given intravenously (IV). Distinct from IV delivery, inhaled IL-15 therapy offers the advantages of concentrated delivery to the lungs, a frequent site of gross metastatic disease, while limiting systemic exposure and potential toxicity. Osteosarcoma (OSA) is an aggressive primary bone cancer with a high propensity for lung metastases, and outcomes for patients with lung metastases have been stagnant for the past 4 decades. In our recently completed (manuscript in preparation) first-in-kind trial of inhaled rhIL-15 in dogs with spontaneous lung metastases from OSA and melanoma, we observed clinical benefit in 37% (1 complete response, 1 partial response, and 5 stable disease at 60 days in 19 dogs). Here, we propose to evaluate the immune mechanisms of response to inhaled IL-15 in mouse and human models of metastatic OSA, hypothesizing that a unique tissue resident NK population in the lungs has heightened cytotoxic and proliferative responses consistent with a memory- like phenotype which enables augmented anti-tumor responses. In Aim 1, we will analyze lung resident NK cells (CD3-NKp46+CD49a+) in K7M2 and LM8 models of OSA, hypothesizing that inhaled IL-15 delivered by nebulizer will stimulate NK-mediated anti-tumor responses against OSA lung metastases. Matched human blood, non-tumor-bearing lung, and tumor samples from patients with OSA undergoing metastasectomy will be used to validate these mouse studies, in particular that human lung NK cells show features of heightened cytotoxicity and effector function which can be harnessed to infiltrate immunosuppressive OSA metastases in the setting on inhaled IL-15. In Aim 2, we will evaluate combination therapy. T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) has emerged as a critical marker of NK cell exhaustion which limits anti-tumor responses in multiple cancer types, including sarcomas. Thus, we will combine inhaled IL-15 with TIGIT blockade using anti-TIGIT monoclonal antibodies to assess NK phenotype and function, trafficking to lung tumors, persistence, and tumor regression following treatment in mouse models. Toxicity will also be carefully assessed given the potential for combination immunotherapy to precipitate immunopathology and cytokine storm. Metastatic OSA is a rare and difficult-to-treat cancer. Despite great success in other cancers, immunotherapy targeting PD-1, PD-L1, and CTLA-4 has shown minimal efficacy in OSA, underscoring the need for novel immunotherapies for these aggressive cancers. This proposal will evaluate novel strategies to stimulate tissue-resident NK cells in the lungs using inhaled IL-15 to maximize the therapeutic exposure at the site of action while limiting systemic exposure and toxicity.",
                "keywords": [
                    "Activated Natural Killer Cell",
                    "Adoptive Transfer",
                    "Advanced Malignant Neoplasm",
                    "Antitumor Response",
                    "Back",
                    "Blood",
                    "CD3 Antigens",
                    "CD8-Positive T-Lymphocytes",
                    "CTLA4 gene",
                    "Cancer Patient",
                    "Canis familiaris",
                    "Cell Death Induction",
                    "Cell Proliferation",
                    "Cellular immunotherapy",
                    "Clinical",
                    "Combination immunotherapy",
                    "Combined Modality Therapy",
                    "Data",
                    "Disease",
                    "Disinhibition",
                    "Dose",
                    "Drug Kinetics",
                    "Exposure to",
                    "Female",
                    "Foundations",
                    "Functional disorder",
                    "Goals",
                    "Homeostasis",
                    "Human",
                    "ITIM",
                    "Immune",
                    "Immunocompetent",
                    "Immunoglobulins",
                    "Immunosuppression",
                    "Immunotherapy",
                    "In complete remission",
                    "Inbred BALB C Mice",
                    "Inbred C3H Mice",
                    "Infiltration",
                    "Inhalation",
                    "Interleukin-15",
                    "Interleukin-2",
                    "Intravenous",
                    "Longevity",
                    "Lung",
                    "Lung Neoplasms",
                    "Lymphokine-Activated Killer Cells",
                    "Malignant Neoplasms",
                    "Manuscripts",
                    "Mediating",
                    "Memory",
                    "Metastatic Neoplasm to the Lung",
                    "Metastatic Osteosarcoma",
                    "Modeling",
                    "Monoclonal Antibodies",
                    "Mus",
                    "Natural Killer Cells",
                    "Nebulizer",
                    "Neoplasm Metastasis",
                    "Outcome Assessment",
                    "Pathway interactions",
                    "Patient-Focused Outcomes",
                    "Patients",
                    "Phenotype",
                    "Play",
                    "Population",
                    "Preparation",
                    "Regulatory T-Lymphocyte",
                    "Resistance",
                    "Risk",
                    "Role",
                    "Sampling",
                    "Site",
                    "Stable Disease",
                    "Structure of parenchyma of lung",
                    "Systemic Therapy",
                    "T cell response",
                    "T memory cell",
                    "T-Lymphocyte",
                    "Testing",
                    "Therapeutic",
                    "Therapeutic Effect",
                    "Tissues",
                    "Toxic effect",
                    "Translations",
                    "Treatment Efficacy",
                    "Tumor Immunity",
                    "Tyrosine",
                    "Up-Regulation",
                    "antitumor effect",
                    "cancer therapy",
                    "cancer type",
                    "cytokine",
                    "cytokine release syndrome",
                    "cytotoxic",
                    "cytotoxicity",
                    "effector T cell",
                    "exhaustion",
                    "human model",
                    "immune checkpoint",
                    "immune checkpoint blockade",
                    "immune function",
                    "immunopathology",
                    "immunoregulation",
                    "improved",
                    "innovation",
                    "male",
                    "melanoma",
                    "mouse model",
                    "novel",
                    "novel strategies",
                    "osteosarcoma",
                    "overexpression",
                    "partial response",
                    "pathogen exposure",
                    "phase I trial",
                    "primary bone cancer",
                    "programmed cell death ligand 1",
                    "programmed cell death protein 1",
                    "response",
                    "sarcoma",
                    "success",
                    "survival outcome",
                    "systemic toxicity",
                    "trafficking",
                    "tumor",
                    "tumor-immune system interactions"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11603",
            "attributes": {
                "award_id": "5R21DE031074-02",
                "title": "Targeting Grainyhead-Like 2 Suppresses Entry Factors of SARS-CoV-2 in Epithelial Cells of Oral Mucosa.",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Dental and Craniofacial Research (NIDCR)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 22517,
                        "first_name": "Preethi",
                        "last_name": "Chander",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-01",
                "end_date": "2024-03-31",
                "award_amount": 195000,
                "principal_investigator": {
                    "id": 22518,
                    "first_name": "WEI",
                    "last_name": "CHEN",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 818,
                            "ror": "",
                            "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES",
                            "address": "",
                            "city": "",
                            "state": "CA",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 818,
                    "ror": "",
                    "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES",
                    "address": "",
                    "city": "",
                    "state": "CA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The long-term goal of our research is to develop effective therapies against SARS-CoV-2-elicited disease Covid-19. SARS-CoV-2 spike (S) protein binds to its cognate receptor, angiotensin-converting enzyme 2 (ACE2), and in concert with host proteases, principally transmembrane serine proteases (TMPRSSs), promotes cellular entry. Co-expressions of these viral entry factors are found in the epithelial cells of many organs, including oral mucosa. Recently, oral mucosa has been found to be a potentially high-risk route of SARS-CoV-2 infection. GRHL2, as a transcriptional factor, modulates epithelial gene expression and plasticity through multiple signaling pathways. ACE2 and TMPRSS2 are strongly expressed in epithelial cells, coinciding with the pattern of GRHL2 expression in oral mucosa. GRHL2 regulates ACE2 and TMPRSS2 expression in normal human oral keratinocytes (NHOK). Ectopic expression of GRHL2 induces ACE2 and TMPRSSs expression, while knockdown of GRHL2 leads to decreased levels of these entry factors. ACE2 is an interferon-stimulated gene. IFN-α activates ACE2 expression in part through regulating GRHL2. Small-molecule inhibitors of GRHL2 suppress viral entry factor expression in NHOK. ACE2 and TMPRSS2 are widely expressed in oral mucosal epithelium, knockout of GRHL2 leads to suppression of ACE2 and TMPRSS2 expression in vivo. These findings indicate that GRHL2 is required for ACE2 and TMPRSS expression in NHOK cultured in vitro and oral mucosal epithelium in vivo. Based on these data, we hypothesize that targeting GRHL2 inhibits SARS-CoV-2 transmission into oral mucosal epithelium through regulating viral entry factor expression. This novel hypothesis will be tested by examining the molecular mechanism underlying GRHL2 regulates expression of SARS-CoV-2 entry factors (ACE2 and TMPRSSs) in oral mucosal epithelial cells. Analysis of variance methods will be used to compare means of these gene expression levels. We will also generate a pseudotyped virus in which vesicular stomatitis virus (VSV) green fluorescent protein (GFP) reporter virus expressing SARS- CoV-2 S in replacement of native glycoprotein. Utilizing this chimeric virus, a high throughput assay will be developed to screen GRHL2 inhibitors, which possess the potentials to abrogate SARS-CoV-2 virus infection into oral mucosal epithelium.",
                "keywords": [
                    "2019-nCoV",
                    "3-Dimensional",
                    "ACE2",
                    "Analysis of Variance",
                    "Binding",
                    "Binding Proteins",
                    "Biological Assay",
                    "COVID-19",
                    "COVID-19 pandemic",
                    "COVID-19 patient",
                    "CRISPR/Cas technology",
                    "Cell Differentiation process",
                    "Cell Proliferation",
                    "Cell Separation",
                    "Cell membrane",
                    "Cells",
                    "Containment",
                    "Data",
                    "Ectopic Expression",
                    "Epigenetic Process",
                    "Epithelial",
                    "Epithelial Cells",
                    "Functional disorder",
                    "Gene Expression",
                    "Genes",
                    "Genetic Transcription",
                    "Gingiva",
                    "Glycoproteins",
                    "Goals",
                    "Green Fluorescent Proteins",
                    "Health",
                    "Human",
                    "In Vitro",
                    "Infection",
                    "Interferon alpha",
                    "Interferons",
                    "Knock-out",
                    "Mediating",
                    "Membrane",
                    "Methods",
                    "Modeling",
                    "Molecular",
                    "Mus",
                    "Oral",
                    "Oral cavity",
                    "Oral mucous membrane structure",
                    "Organ",
                    "Outcome",
                    "Pattern",
                    "Peptide Hydrolases",
                    "Play",
                    "Predisposition",
                    "Process",
                    "Public Health",
                    "Publishing",
                    "Reporter",
                    "Research",
                    "Role",
                    "Route",
                    "SARS-CoV-2 infection",
                    "SARS-CoV-2 inhibitor",
                    "SARS-CoV-2 spike protein",
                    "SARS-CoV-2 transmission",
                    "Salivary Glands",
                    "Serine Protease",
                    "Signal Pathway",
                    "Site",
                    "TMPRSS2 gene",
                    "Testing",
                    "Tissues",
                    "Transcriptional Regulation",
                    "Transduction Gene",
                    "Tropism",
                    "Vesicular stomatitis Indiana virus",
                    "Viral",
                    "Virus",
                    "Virus Diseases",
                    "coronavirus disease",
                    "effective therapy",
                    "experimental study",
                    "gain of function",
                    "high risk",
                    "high throughput screening",
                    "in vivo",
                    "inhibitor",
                    "keratinocyte",
                    "knock-down",
                    "knockout gene",
                    "monolayer",
                    "mouse model",
                    "new therapeutic target",
                    "novel",
                    "oral cavity epithelium",
                    "promoter",
                    "receptor",
                    "screening",
                    "small molecule inhibitor",
                    "transcription factor",
                    "translational potential",
                    "viral entry inhibitor"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11604",
            "attributes": {
                "award_id": "5U01NR020556-02",
                "title": "A National Neighborhood Data Resource to Understand Inequities in the Health and Socioeconomic Impacts of COVID-19 in the United States",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute on Minority Health and Health Disparities (NIMHD)",
                    "National Institute of Nursing Research (NINR)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 6234,
                        "first_name": "Dionne",
                        "last_name": "Godette",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-14",
                "end_date": "2027-01-31",
                "award_amount": 763796,
                "principal_investigator": {
                    "id": 6235,
                    "first_name": "Philippa",
                    "last_name": "Clarke",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 770,
                            "ror": "",
                            "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR",
                            "address": "",
                            "city": "",
                            "state": "MI",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [
                    {
                        "id": 6236,
                        "first_name": "Grace A",
                        "last_name": "Noppert",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 770,
                    "ror": "",
                    "name": "UNIVERSITY OF MICHIGAN AT ANN ARBOR",
                    "address": "",
                    "city": "",
                    "state": "MI",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "The COVID-19 pandemic has resulted in substantial changes to American neighborhoods in ways that are only beginning to be elucidated. There has been an excess of permanent business closures, particularly among small neighborhood businesses most vulnerable to social distancing, such as local barber shops and nail salons. COVID-19 outbreaks in late September 2021 caused 2,000 neighborhood schools to close for an average of six days in 39 states. A burgeoning body of research has tried to understand the forces driving these trends, focusing on infectious disease transmission at the individual level or economic models at the business level. What is not considered is the context in which these changes are taking place. By context, we mean the neighborhood community environment that holds the opportunities, restrictions, risks, and flexibility for post-pandemic growth, including job opportunities in business sectors robust to social distancing; comprehensive broadband internet access to facilitate telemedicine, online schooling, remote work, and online grocery shopping; parks and walkable streets to facilitate socially distanced physical activity and social interaction to mitigate social isolation brought on by the pandemic; and the provision of medical care through the availability of alternate health care providers and pharmacies. Access to these neighborhood resources is not equally distributed across America, reinforcing risk for vulnerable populations, including older adults, children and adolescents, racial/ethnic minorities, and those in rural areas. However, a lack of national, standardized, longitudinal metrics of the local neighborhood environment has hindered the ability to identify which communities are most vulnerable to the immediate and longer-term consequences of the pandemic for a host of behavioral, psychological, social, and economic outcomes. To address this limitation in the nation's data infrastructure, we will augment, curate and disseminate data from our National Neighborhood Data Archive (NaNDA), which includes a wealth of physical, social and economic characteristics of the local neighborhood across the United States (e.g., racial segregation, business density, environmental hazards, broadband internet access, and healthcare availability), in the years both before and since the pandemic. We will participate with the Consortium on Social, Behavioral, and Economic Research on COVID-19 to integrate, share, and analyze spatially referenced neighborhood data that can be readily linked to existing survey data, cohort studies, or electronic health records at various levels of geography. We will work with the COVID-19 Consortium Coordination Center to identify and create key neighborhood metrics that are priorities for research teams in the Consortium, including a set of common data elements (CDEs) on the social, behavioral and economic indicators of the COVID-19 pandemic at the neighborhood level. We will also develop new metrics of longitudinal neighborhood change in the decades preceding the pandemic, which can inform community risk and resilience since the pandemic.",
                "keywords": [
                    "Address",
                    "Adolescent",
                    "Age",
                    "American",
                    "Area",
                    "Barbering",
                    "Behavioral",
                    "Businesses",
                    "COVID-19",
                    "COVID-19 impact",
                    "COVID-19 outbreak",
                    "COVID-19 pandemic",
                    "COVID-19 pandemic effects",
                    "Caring",
                    "Censuses",
                    "Characteristics",
                    "Child",
                    "Clinical Research",
                    "Cohort Studies",
                    "Common Data Element",
                    "Communities",
                    "County",
                    "Data",
                    "Economic Models",
                    "Economics",
                    "Education",
                    "Educational workshop",
                    "Elderly",
                    "Electronic Health Record",
                    "Employment",
                    "Environment",
                    "Environmental Hazards",
                    "Ethnic Origin",
                    "Funding",
                    "Geography",
                    "Growth",
                    "Health",
                    "Health Personnel",
                    "Health Promotion",
                    "Individual",
                    "Infrastructure",
                    "Internet",
                    "Letters",
                    "Libraries",
                    "Link",
                    "Locales",
                    "Loneliness",
                    "Maps",
                    "Measures",
                    "Medical",
                    "Mental Health",
                    "Nail plate",
                    "Neighborhoods",
                    "Occupations",
                    "Pattern",
                    "Pharmacy facility",
                    "Physical activity",
                    "Policies",
                    "Politics",
                    "Population",
                    "Race",
                    "Racial Segregation",
                    "Recording of previous events",
                    "Research",
                    "Research Priority",
                    "Resources",
                    "Risk",
                    "Role",
                    "Schools",
                    "Shapes",
                    "Social Distance",
                    "Social Interaction",
                    "Social isolation",
                    "Social outcome",
                    "Source",
                    "Standardization",
                    "Structure",
                    "Surveys",
                    "Telemedicine",
                    "Underserved Population",
                    "United States",
                    "Universities",
                    "Update",
                    "Visualization",
                    "Vulnerable Populations",
                    "Work",
                    "archive data",
                    "behavioral outcome",
                    "data archive",
                    "data curation",
                    "data infrastructure",
                    "data resource",
                    "data sharing",
                    "density",
                    "disease transmission",
                    "driving force",
                    "economic impact",
                    "economic indicator",
                    "economic outcome",
                    "ethnic minority",
                    "experience",
                    "flexibility",
                    "health care availability",
                    "health economics",
                    "health inequalities",
                    "innovation",
                    "pandemic disease",
                    "post-pandemic",
                    "psychological outcomes",
                    "public health emergency",
                    "racial minority",
                    "resilience",
                    "response",
                    "rural area",
                    "school environment",
                    "skills",
                    "social",
                    "socioeconomic disadvantage",
                    "socioeconomics",
                    "substance use",
                    "tool",
                    "trend",
                    "volunteer",
                    "walkability"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11605",
            "attributes": {
                "award_id": "5R35GM144124-02",
                "title": "MECHANISMS AND MACROMOLECULAR INTERACTIONS UNDERLYING CELLULAR RESPONSES TO STRESS SIGNALS",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of General Medical Sciences (NIGMS)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 27542,
                        "first_name": "Marc",
                        "last_name": "Rigas",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-01",
                "end_date": "2027-03-31",
                "award_amount": 398750,
                "principal_investigator": {
                    "id": 22608,
                    "first_name": "Alexandra M.",
                    "last_name": "Deaconescu",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 222,
                            "ror": "https://ror.org/05gq02987",
                            "name": "Brown University",
                            "address": "",
                            "city": "",
                            "state": "RI",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 222,
                    "ror": "https://ror.org/05gq02987",
                    "name": "Brown University",
                    "address": "",
                    "city": "",
                    "state": "RI",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Proteins carrying out DNA repair, replication and transcription, processes essential for the stable transmission and expression of genomic information, share the same track – the DNA – and require delicate coordination to achieve their function. Often, regulation of these processes occurs at the level of targeting or well-timed recruitment, but also catalysis and even turnover of the factor in question. We will address these three principal modalities of regulation in the context of bacterial responses to stress signals. Our questions and hypotheses are grouped into two large areas, (1) regulation of the general stress response mediated by the promoter specificity subunit RpoS; this is exemplary of a general stress response mechanism that affect transcription initiation, and (2) specific responses to DNA damage such as subpathways of nucleotide excision repair; these are exemplary of how the DNA damage response interfaces with transcription elongation, termination as well as replication. The principal questions that will be addressed by my research plan are: A. How are activating and inhibitory regulatory inputs integrated to tune the RpoS core pathway and  globally reprogram transcription in response to an adverse environment? How does the ClpXP  adaptor RssB and stress-specific ClpXP anti-adaptors tune the proteolysis of RpoS in a stress-specific manner? B. What are the mechanisms for preferential recruitment of the NER machinery to specific lesions,  or to the template strand, directly read by RNA polymerase? How is the availability of early NER  factors regulated by proteolysis in the context of DNA damage and transcription-coupled DNA repair?  How and when do transcription-repair coupling factors collaborate with key players in the SOS response  to promote mutagenesis? Can we leverage these mechanisms towards developing novel anti-evolution  drugs for combination therapies against infection with diverse pathogens? Previous work has already allowed us to build a critical collection of reagents and expertise in the structural biology and biochemistry of transcription-coupled repair and RpoS biology. This gives us now an excellent entry point for a mechanistic dissection of the processes listed above and the development of novel antimicrobial strategies. The significance of our work is thus not only fundamental and conceptual in nature, but has immediate applications in controlling the worldwide public health crisis of antimicrobial resistance, particularly in the age of the COVID-19 pandemic.",
                "keywords": [
                    "Address",
                    "Affect",
                    "Age",
                    "Antibiotics",
                    "Antimicrobial Resistance",
                    "Area",
                    "Bacteria sigma factor KatF protein",
                    "Biology",
                    "COVID-19 pandemic",
                    "Catalysis",
                    "Collaborations",
                    "Collection",
                    "Combination Drug Therapy",
                    "Coupled",
                    "Coupling",
                    "DNA",
                    "DNA Damage",
                    "DNA Repair",
                    "DNA-Directed RNA Polymerase",
                    "Development",
                    "Dissection",
                    "Environment",
                    "Evolution",
                    "Genetic Transcription",
                    "Genomics",
                    "Infection",
                    "Lesion",
                    "Mediating",
                    "Modality",
                    "Molecular Evolution",
                    "Mutagenesis",
                    "Nature",
                    "Nucleotide Excision Repair",
                    "Organism",
                    "Pathway interactions",
                    "Process",
                    "Proteins",
                    "Proteolysis",
                    "Public Health",
                    "Reagent",
                    "Regulation",
                    "Research",
                    "SOS Response",
                    "Signal Transduction",
                    "Specificity",
                    "Stress",
                    "Structural Biochemistry",
                    "Transcription Elongation",
                    "Transcription Initiation",
                    "Transcription-Coupled Repair",
                    "Work",
                    "antimicrobial",
                    "biological adaptation to stress",
                    "cross immunity",
                    "novel",
                    "pathogen",
                    "programs",
                    "promoter",
                    "recruit",
                    "repaired",
                    "response",
                    "stressor",
                    "structural biology",
                    "transmission process"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11606",
            "attributes": {
                "award_id": "5D43TW011818-02",
                "title": "Mali-Guinea Emerging Infectious Disease Research Training Program (Mali-Guinea EID-RTP)",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)",
                    "Fogarty International Center (FIC)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 8091,
                        "first_name": "Barbara J",
                        "last_name": "Sina",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-01",
                "end_date": "2027-02-28",
                "award_amount": 233378,
                "principal_investigator": {
                    "id": 22635,
                    "first_name": "SEYDOU",
                    "last_name": "DOUMBIA",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1519,
                            "ror": "",
                            "name": "UNIV OF SCIENCES, TECH & TECH OF BAMAKO",
                            "address": "",
                            "city": "",
                            "state": "",
                            "zip": "",
                            "country": "MALI",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 1519,
                    "ror": "",
                    "name": "UNIV OF SCIENCES, TECH & TECH OF BAMAKO",
                    "address": "",
                    "city": "",
                    "state": "",
                    "zip": "",
                    "country": "MALI",
                    "approved": true
                },
                "abstract": "The recent epidemics of Ebola in West Africa and the current COVID-19 pandemic highlight the need for a critical mass of well-trained scientists and public health research professionals capable of studying and responding appropriately, and a in timely manner, to emerging infectious diseases (EID) threats. This competitive new application supports a new training program on EIDs in Mali and Guinea. This will build upon and expand the scope of the existing FIC/NIH D43 training program based in the Department of Public Health at the University of Sciences, Techniques and Technologies of Bamako (USTTB) and leverage on existing NIAID collaborative research programs in the two countries. The existing D43 training program has a focus on malaria and neglected tropical diseases (NTDs), but does not include training and other capacity-building in surveillance, laboratory diagnosis, and control of viral pathogens such as Ebola Virus Disease, COVID-19 and Lassa Fever. With maturation of our training and research on malaria and NTDs, and an increased supply of highly qualified mentors and trainees in Mali, we propose an increased emphasis on training on EIDs in Mali and Guinea and mentoring by Malian, Guinean and US researchers. This training program will provide a curriculum for training doctoral and master’s students in advanced field epidemiology and laboratory practices, as well as non-degree certifications (professional skill enhancement) in translational clinical research, public health emergency management and genomic surveillance of emerging infectious pathogens, preparing Guinea and Mali to better handle potential future epidemics. This program is a south-south collaboration effort between Guinea and Mali, supported by Johns Hopkins School of Public Health (JHSPH), to have researchers from both sides collaborate more closely on these cross-border diseases for more coordinated and efficient public health responses. The training program will support six doctoral students and 15 master’s students. Dissertation of Doctoral and Master thesis research will include research questions related or applicable to Ebola and other EIDs. Supported students will take courses from, and be mentored by, faculty from the University of Conakry, USTTB, and JHSPH. Selected students will have the opportunity to take online courses at JHSPH that are not offered at the University of Conakry or USTTB. The program will also provide faculty enrichment through training and coursework for eight faculty members, which may include trainings or online coursework at JHSPH and will provide laboratory training for five research scientists (students or faculty). Short courses will also be offered twice per year, training 120 public health professionals and young scientists in topics related to the control of EIDs. This support will greatly enhance capacity in Guinea and Mali to respond to and control impending outbreaks of EIDs in their own countries, and in the West African region.",
                "keywords": [
                    "Africa",
                    "African",
                    "Border Crossings",
                    "COVID-19",
                    "COVID-19 pandemic",
                    "Certification",
                    "Clinical Research",
                    "Collaborations",
                    "Country",
                    "Disease",
                    "Ebola",
                    "Ebola Hemorrhagic Fever",
                    "Educational Curriculum",
                    "Emerging Communicable Diseases",
                    "Epidemic",
                    "Epidemiology",
                    "Faculty",
                    "Genomics",
                    "Guinea",
                    "Health Professional",
                    "Infectious Diseases Research",
                    "Laboratories",
                    "Laboratory Diagnosis",
                    "Lassa Fever",
                    "Malaria",
                    "Mali",
                    "Mentors",
                    "National Institute of Allergy and Infectious Disease",
                    "Public Health",
                    "Public Health Schools",
                    "Qualifying",
                    "Research",
                    "Research Personnel",
                    "Science",
                    "Scientist",
                    "Side",
                    "Student Selections",
                    "Students",
                    "Training",
                    "Training Programs",
                    "United States National Institutes of Health",
                    "Universities",
                    "clinical translation",
                    "doctoral student",
                    "future epidemic",
                    "laboratory experience",
                    "member",
                    "neglected tropical diseases",
                    "new outbreak",
                    "online course",
                    "pathogen",
                    "pathogenic virus",
                    "programs",
                    "public health emergency",
                    "public health research",
                    "response",
                    "skills",
                    "technology/technique"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11607",
            "attributes": {
                "award_id": "5U19AI167899-02",
                "title": "Research Project 1 - The pregnancy ImmunOME",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Allergy and Infectious Diseases (NIAID)"
                ],
                "program_reference_codes": [],
                "program_officials": [],
                "start_date": "2022-04-19",
                "end_date": "2027-03-31",
                "award_amount": 747949,
                "principal_investigator": {
                    "id": 21683,
                    "first_name": "Andrea Goldberg",
                    "last_name": "Edlow",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 736,
                            "ror": "https://ror.org/002pd6e78",
                            "name": "Massachusetts General Hospital",
                            "address": "",
                            "city": "",
                            "state": "MA",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [],
                "awardee_organization": {
                    "id": 210,
                    "ror": "https://ror.org/042nb2s44",
                    "name": "Massachusetts Institute of Technology",
                    "address": "",
                    "city": "",
                    "state": "MA",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Project 1: Summary The COVID-19 pandemic has revolutionized our ability to decode the rules of maternal immunity. There is a significant gap in knowledge regarding innate and adaptive immune responses over the course of pregnancy and how trimester-specific perturbations in the maternal immunological signature might manifest in attributable risk or benefit to the maternal-fetal dyad. The COVID-19 vaccines and their real-world use by pregnant women present a unique opportunity to define the baseline, trimester-specific immune signature, and to examine the maternal immune response after in vivo perturbation with both de novo (never before seen by the immune system) and recall (boosted responses such as influenza and pertussis) vaccines across the trimesters of pregnancy. In Project 1 in the Maternal ‘Omics to Maximize Immunity (MOMi) consortium, we propose to apply a multi-‘OMICs approach to deeply and comprehensively capture shifts in the maternal immune response before and after maternal immunization across pregnancy. We will profile maternal peripheral blood mononuclear cells, plasma, placental cell isolates, and stool from pre- and post-maternal vaccination, using single cell RNA-Seq (scRNA-Seq), Assay for Transposase-Accessible Chromatin with high-throughput sequencing (scATAC-Seq), Cellular Indexing of Transcriptomes and Epitopes by Sequencing (scCITE-Seq), proteomics, metabolomics, and metagenomics, and integrate all data through the Data Management and Analysis Core (DMAC). In collaboration with Project 2, the ultimate goal is to define maternal immunity longitudinally across pregnancy trimesters in the normal baseline and vaccinated state, in order to build the most comprehensive Pregnancy Immune Atlas of innate and adaptive immune profiling across the maternal-fetal dyad. We will examine how the cellular transcriptome, microbiome, metabolome, and proteome shifts over the course of pregnancy, and how they are modified in response to different vaccine platforms (mRNA, adenovirus, adjuvanted protein) and types (de novo versus recall), providing a unique opportunity to profile the maternal immune response with unprecedented resolution. This detailed map of pregnancy immunity will generate critical data to open previously unrecognized therapeutic windows in this unusual and understudied area of human immunology.",
                "keywords": [
                    "Address",
                    "Adenoviruses",
                    "Adjuvant",
                    "Age",
                    "Antigens",
                    "Area",
                    "Atlases",
                    "Biological Assay",
                    "Body mass index",
                    "COVID-19 pandemic",
                    "COVID-19 vaccination",
                    "COVID-19 vaccine",
                    "Cell Separation",
                    "Cells",
                    "Cellular Assay",
                    "Cellular Indexing of Transcriptomes and Epitopes by Sequencing",
                    "Characteristics",
                    "Child",
                    "Chromatin",
                    "Clinical",
                    "Collaborations",
                    "Complex",
                    "Data",
                    "Data Analyses",
                    "Disease",
                    "Enrollment",
                    "Ensure",
                    "Equilibrium",
                    "Fc Receptor",
                    "Feces",
                    "Future",
                    "Goals",
                    "High-Throughput Nucleotide Sequencing",
                    "Human",
                    "Immune",
                    "Immune Tolerance",
                    "Immune response",
                    "Immune system",
                    "Immunity",
                    "Immunologics",
                    "Immunology",
                    "In Vitro",
                    "Infant",
                    "Infection",
                    "Inflammation",
                    "Influenza",
                    "Infrastructure",
                    "Innate Immune Response",
                    "Knowledge",
                    "Maps",
                    "Maternal Mortality",
                    "Maternally-Acquired Immunity",
                    "Messenger RNA",
                    "Metabolic Diseases",
                    "Metagenomics",
                    "Mothers",
                    "Peripheral Blood Mononuclear Cell",
                    "Pertussis",
                    "Pertussis Vaccine",
                    "Plasma",
                    "Population",
                    "Pregnancy",
                    "Pregnancy Trimesters",
                    "Pregnant Women",
                    "Proliferating",
                    "Proteins",
                    "Proteome",
                    "Proteomics",
                    "Recording of previous events",
                    "Research Project Grants",
                    "Resolution",
                    "Risk",
                    "SARS-CoV-2 negative",
                    "Sampling",
                    "Shapes",
                    "Shotguns",
                    "Systems Biology",
                    "Therapeutic",
                    "Time",
                    "Transposase",
                    "Vaccinated",
                    "Vaccination",
                    "Vaccine Design",
                    "Vaccines",
                    "Woman",
                    "Work",
                    "adaptive immune response",
                    "antibody transfer",
                    "booster vaccine",
                    "cell type",
                    "cohort",
                    "data integration",
                    "data management",
                    "early pregnancy",
                    "emerging pathogen",
                    "experimental study",
                    "fetal",
                    "gut microbiome",
                    "healthy pregnancy",
                    "high dimensionality",
                    "in vivo",
                    "influenza virus vaccine",
                    "insight",
                    "maternal immune system",
                    "maternal vaccination",
                    "metabolome",
                    "metabolomics",
                    "metagenomic sequencing",
                    "microbial",
                    "microbiome",
                    "multidisciplinary",
                    "neonate",
                    "next generation",
                    "novel",
                    "pandemic disease",
                    "pathogen",
                    "placental transfer",
                    "prospective",
                    "receptor expression",
                    "response",
                    "sex",
                    "single-cell RNA sequencing",
                    "therapeutic development",
                    "transcriptome",
                    "vaccine development",
                    "vaccine platform",
                    "vaccine response",
                    "vaccine strategy"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11608",
            "attributes": {
                "award_id": "5R21GM146142-02",
                "title": "Multiomic, mass spectrometry-based analysis of dried blood for deep phenotyping of sepsis",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of General Medical Sciences (NIGMS)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 22300,
                        "first_name": "XIAOLI",
                        "last_name": "Zhao",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-01",
                "end_date": "2024-03-31",
                "award_amount": 237615,
                "principal_investigator": {
                    "id": 22673,
                    "first_name": "Matthew Wolf",
                    "last_name": "Foster",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 246,
                            "ror": "https://ror.org/00py81415",
                            "name": "Duke University",
                            "address": "",
                            "city": "",
                            "state": "NC",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [
                    {
                        "id": 22674,
                        "first_name": "TIMOTHY J",
                        "last_name": "MCMAHON",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 246,
                    "ror": "https://ror.org/00py81415",
                    "name": "Duke University",
                    "address": "",
                    "city": "",
                    "state": "NC",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Sepsis, which is characterized by life threatening organ dysfunction caused by an uncontrolled host response to infection, is the leading cause of death in hospitals and is responsible for >250,000 deaths per year in the U.S. at the cost of over $20 billion in patient care. Sepsis has a mortality rate nearing 50% at 2 years, which has profound implications for patients recovering from severe COVID-19, a form of viral sepsis. Because sepsis is a multi-organ disease, the quantification of circulating proteins and metabolites is central to the profiling of sepsis and of its long-term effects, and some such assays (lactate, procalcitonin) have become the standard of care. To date, the majority of studies, and particularly the large number in COVID-19 sepsis, have profiled plasma and serum, which, compared to whole blood is fraught with variability and belies the important roles of the erythrocyte and other cell-types. To this end, biorepositories at Duke University, which are banking samples from COVID- 19 sepsis patients in the intensive care unit (ICU) and in a post-COVID outpatient clinic, have been utilizing volumetric absorptive microsampling (VAMS) on Neoteryx Mitra tips to collect and store whole blood specimens for future ‘omic analyses. The overarching goals of this application are to develop and validate multiomic methods for mass spectrometry-based quantification of proteins and metabolites from Mitra tips that comprehensively profile sepsis pathobiology. In the R21 phase, we will develop and validate mass spectrometry-based methods for the non-targeted quantification of proteins and post-translational modifications (phosphorylation, glycosylation) in whole blood, and for targeted quantification of numerous metabolite classes. We will develop reference materials and standard operating procedures for inter-laboratory translation of these approaches. In the R33 phase, we will analyze proteins, PTMs and metabolites from over 600 patient timepoints from biorepositories containing longitudinal samples in critically ill sepsis and post-COVID-19 cohorts, and we will integrate these data with well-curated clinical datasets. Completion of these aims will establish the utility of blood sampling by VAMS for future sepsis studies and will create a highly curated clinical and deep multiomic dataset for future hypothesis generation.",
                "keywords": [
                    "Address",
                    "Adoption",
                    "Affect",
                    "Ambulatory Care Facilities",
                    "Antibiotics",
                    "Biological Assay",
                    "Biology",
                    "Blood",
                    "Blood specimen",
                    "C-reactive protein",
                    "COVID-19",
                    "Cause of Death",
                    "Cells",
                    "Cessation of life",
                    "Clinical",
                    "Clinical Data",
                    "Clinical Management",
                    "Code",
                    "Collecting Cell",
                    "Collection",
                    "Coupled",
                    "Critical Illness",
                    "Data",
                    "Data Set",
                    "Development",
                    "Devices",
                    "Disease",
                    "Dryness",
                    "Electronic Health Record",
                    "Erythrocytes",
                    "Exhibits",
                    "Functional disorder",
                    "Future",
                    "Generations",
                    "Goals",
                    "Hospitals",
                    "IV Fluid",
                    "Immune response",
                    "Immune signaling",
                    "In Vitro",
                    "Infection",
                    "Intensive Care Units",
                    "Laboratories",
                    "Life",
                    "Liquid Chromatography",
                    "Long-Term Effects",
                    "Mass Spectrum Analysis",
                    "Metabolism",
                    "Methodology",
                    "Methods",
                    "Morbidity - disease rate",
                    "Multiomic Data",
                    "Organ",
                    "Outcome",
                    "Pathway Analysis",
                    "Pathway interactions",
                    "Patient Care",
                    "Patient Selection",
                    "Patients",
                    "Persons",
                    "Phase",
                    "Phenotype",
                    "Phosphorylation",
                    "Pilot Projects",
                    "Plasma",
                    "Post-Translational Protein Processing",
                    "Preparation",
                    "Procedures",
                    "Proteins",
                    "Proteome",
                    "Proteomics",
                    "Pythons",
                    "Quality Control",
                    "Recovery",
                    "Reporting",
                    "Role",
                    "Sampling",
                    "Sepsis",
                    "Serum",
                    "Shipping",
                    "Signal Pathway",
                    "Signal Transduction",
                    "Standardization",
                    "Techniques",
                    "Tissues",
                    "Translations",
                    "Universities",
                    "Validation",
                    "Viremia",
                    "Whole Blood",
                    "Work",
                    "biobank",
                    "cell type",
                    "cohort",
                    "cost",
                    "data integration",
                    "data repository",
                    "demographics",
                    "glycosylation",
                    "high throughput screening",
                    "metabolome",
                    "metabolomics",
                    "mortality",
                    "multidisciplinary",
                    "multiple omics",
                    "novel",
                    "post-COVID-19",
                    "procalcitonin",
                    "protein profiling",
                    "septic patients",
                    "severe COVID-19",
                    "stability testing",
                    "standard of care",
                    "tandem mass spectrometry",
                    "translational approach",
                    "translational scientist"
                ],
                "approved": true
            }
        },
        {
            "type": "Grant",
            "id": "11609",
            "attributes": {
                "award_id": "5R01DE031928-02",
                "title": "Initiation of immune responses to SARS COV2 in the oral cavity and upper airway",
                "funder": {
                    "id": 4,
                    "ror": "https://ror.org/01cwqze88",
                    "name": "National Institutes of Health",
                    "approved": true
                },
                "funder_divisions": [
                    "National Institute of Dental and Craniofacial Research (NIDCR)"
                ],
                "program_reference_codes": [],
                "program_officials": [
                    {
                        "id": 22517,
                        "first_name": "Preethi",
                        "last_name": "Chander",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "start_date": "2022-04-01",
                "end_date": "2027-03-31",
                "award_amount": 764740,
                "principal_investigator": {
                    "id": 22696,
                    "first_name": "GILL",
                    "last_name": "DIAMOND",
                    "orcid": null,
                    "emails": "",
                    "private_emails": "",
                    "keywords": null,
                    "approved": true,
                    "websites": null,
                    "desired_collaboration": null,
                    "comments": null,
                    "affiliations": [
                        {
                            "id": 1506,
                            "ror": "",
                            "name": "UNIVERSITY OF MISSISSIPPI MED CTR",
                            "address": "",
                            "city": "",
                            "state": "MS",
                            "zip": "",
                            "country": "United States",
                            "approved": true
                        }
                    ]
                },
                "other_investigators": [
                    {
                        "id": 22697,
                        "first_name": "SARAH C",
                        "last_name": "GLOVER",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    },
                    {
                        "id": 22698,
                        "first_name": "BRUCE H.",
                        "last_name": "HORWITZ",
                        "orcid": null,
                        "emails": "",
                        "private_emails": "",
                        "keywords": null,
                        "approved": true,
                        "websites": null,
                        "desired_collaboration": null,
                        "comments": null,
                        "affiliations": []
                    }
                ],
                "awardee_organization": {
                    "id": 1506,
                    "ror": "",
                    "name": "UNIVERSITY OF MISSISSIPPI MED CTR",
                    "address": "",
                    "city": "",
                    "state": "MS",
                    "zip": "",
                    "country": "United States",
                    "approved": true
                },
                "abstract": "Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), a life-threatening illness with multi-system involvement in a subset of infected individuals. Oral and nasopharyngeal (NP) epithelial cells express the SARS-CoV-2 receptor ACE2, and infection of the oral/nasopharyngeal cavity (ONP) is likely an obligate step in the development of COVID-19. Immune responses first generated in the ONP are almost certainly crucial for viral clearance but may also play a central role in the development of hyperinflammatory injury observed in many infected individuals. We have used single cell (sc)- RNA sequencing from a racially diverse prospective cohort of COVID-19 patients to identify distinct subsets of ciliated epithelial cells within the NP that are direct targets for SARS-CoV-2 infection and have described innate anti-viral responses generated by those cells within both directly infected as well as non-infected bystander cells. Interestingly this analysis demonstrates that increased mortality is linked to blunted anti-viral gene response in the NP, suggesting that a successful innate response to viral infection in the nose is a critical component of a successful anti-viral response. In addition to the nose, there is strong evidence that SARS-CoV-2 can infect the oral epithelium. While there are several anatomic sites within the mouth that are likely involved in anti-viral responses, the gingival sulcus is a unique immunologically active location that is crucial for maintaining oral health. The gingival epithelium expresses both the SARS-CoV-2 receptor ACE2 as well as the host protease TMPRSS2 necessary for viral entry, but exhibits important immunological differences compared to the nasal epithelium including a bias towards IL-17 associated neutrophil responses. Thus, our overall hypothesis is that identifying and enhancing successful innate and adaptive cellular immune responses of the nasal and gingival epithelium will lead to novel therapeutic avenues for COVID-19. To address this hypothesis, propose the following aims: 1. Stratify cell states and viral dynamics across mucosal surfaces following SARS-CoV-2 infection and vaccination; 2. Compare memory T cell responses within the nose and gingiva that are associated with successful or pathogenic responses to SARS-CoV-2; and 3. Characterize the regulation of host innate immune defense mechanisms that are essential to limit propagation of SARS-CoV-2 infection within ONP epithelial cells. To accomplish these aims, we will analyze human ONP samples from individuals with COVID- 19, recovered from COVID-19, and vaccinated for COVID-19 using sc-RNA-seq, flow cytometry, and other molecular biology techniques. At completion, the project will define the protective innate and adaptive immune mechanisms operating in the ONP of patients infected with SARS-CoV-2, improve our overall understanding of viral induced immunity in the ONP, and provide insight into how these pathways influence disease pathogenesis.",
                "keywords": [
                    "2019-nCoV",
                    "3-Dimensional",
                    "ACE2",
                    "Acute",
                    "Address",
                    "Aerodigestive Tract",
                    "Affect",
                    "Anatomy",
                    "Antiviral Response",
                    "Area",
                    "Bioinformatics",
                    "COVID-19",
                    "COVID-19 patient",
                    "Cells",
                    "Cessation of life",
                    "Clinical",
                    "Complement",
                    "Coughing",
                    "Defect",
                    "Defense Mechanisms",
                    "Development",
                    "Disease",
                    "Enrollment",
                    "Epithelial",
                    "Epithelial Cells",
                    "Exhibits",
                    "Fever",
                    "Flow Cytometry",
                    "Functional disorder",
                    "Future",
                    "Gene Expression",
                    "Generations",
                    "Genes",
                    "Gingiva",
                    "Goals",
                    "Host Defense",
                    "Human",
                    "IL17 gene",
                    "Immune",
                    "Immune response",
                    "Immunity",
                    "Immunization",
                    "Immunologics",
                    "Immunology",
                    "Immunomodulators",
                    "Individual",
                    "Infection",
                    "Inflammatory",
                    "Inflammatory Response",
                    "Injury",
                    "Interdisciplinary Study",
                    "Interferons",
                    "Interleukin-17",
                    "Knowledge",
                    "Life",
                    "Link",
                    "Location",
                    "Metadata",
                    "Molecular Biology Techniques",
                    "Morbidity - disease rate",
                    "Mucous Membrane",
                    "Nasal Epithelium",
                    "Nasopharynx",
                    "Nose",
                    "Oral",
                    "Oral cavity",
                    "Oral health",
                    "Pathogenesis",
                    "Pathogenicity",
                    "Pathway interactions",
                    "Peptide Hydrolases",
                    "Peptides",
                    "Pharyngeal structure",
                    "Phenotype",
                    "Play",
                    "Preventive",
                    "Production",
                    "Prospective cohort",
                    "Regulation",
                    "Respiratory Signs and Symptoms",
                    "Role",
                    "SARS-CoV-2 infection",
                    "SARS-CoV-2 spike protein",
                    "Sampling",
                    "Severe Acute Respiratory Syndrome",
                    "Severity of illness",
                    "Signal Transduction",
                    "Site",
                    "Sore Throat",
                    "Structure of gingival sulcus",
                    "Surface",
                    "System",
                    "Systemic disease",
                    "T cell receptor repertoire sequencing",
                    "T cell response",
                    "T memory cell",
                    "T-Cell Receptor",
                    "T-Lymphocyte",
                    "T-cell receptor repertoire",
                    "TMPRSS2 gene",
                    "Talents",
                    "Therapeutic",
                    "Tissues",
                    "Type 2 Angiotensin II Receptor",
                    "Vaccinated",
                    "Vaccination",
                    "Vaccinee",
                    "Vaccines",
                    "Viral",
                    "Viral Genes",
                    "Virus",
                    "Virus Diseases",
                    "antiviral immunity",
                    "body system",
                    "cohort",
                    "cytokine",
                    "density",
                    "ethnic diversity",
                    "exhaustion",
                    "improved",
                    "in vivo",
                    "insight",
                    "mitochondrial dysfunction",
                    "mortality",
                    "neutrophil",
                    "next generation",
                    "novel therapeutics",
                    "oral biology",
                    "oral cavity epithelium",
                    "oral infection",
                    "pathogen",
                    "patient population",
                    "patient subsets",
                    "post SARS-CoV-2 infection",
                    "racial diversity",
                    "receptor",
                    "response",
                    "single-cell RNA sequencing",
                    "virology"
                ],
                "approved": true
            }
        }
    ],
    "meta": {
        "pagination": {
            "page": 1392,
            "pages": 1442,
            "count": 14420
        }
    }
}